openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Discover

Markets

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Foralumab — news, coverage & facts — IJR

|NewsJournalsTopicForalumab

Topic

Foralumab

chemical compound

7 members

Feed News Media Community Answers Map About

7 memberscoverage spread: L0/C100/R0

Comments

Ask this entity anything:

Free account · your comment posts right after signup

Business
Tiziana Executive Chairman Raises Stake to 34.93%
Tiziana Life Sciences’ Executive Chairman Gabriele Cerrone has quietly increased his stake to 34.93% via Panetta Partners, purchasing 42,357 shares at $0.99, signaling strong insider confidence in the clinical-stage biotech’s lead asset intranasal foralumab. The move could bolster governance, financing, and partnership prospects as the company advances its MS-focused immunomodulation programs.
5 sources

Facts from Wikidata (CC0).

Foralumab (TZLS-401), being researched by Tiziana Life Sciences) is a fully human monoclonal antibody that binds to CD3 epsilon of the T cell receptor-CD3 complex. It is currently being studied in a randomized, double-blind placebo-controlled, multicenter dose-ranging study in a nasal formulation in patients with non-active secondary progressive multiple sclerosis (SPMS).

Read the full article →